NanOlogy concludes subject enrolment in Phase IIa lung cancer trial

NanOlogy has concluded subject enrolment in a Phase IIa clinical trial of large surface area microparticle paclitaxel (LSAM-PTX) plus standard of care (SOC) therapy in non-operable lung cancer patients.